



Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 17, 2026-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 3:20 p.m. ET.

Interested parties can access the live webcast [here](#). An archived copy of the webcast will be available on the [events](#) section of the Company's website for approximately 90 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on [X](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260217981476/en/): <https://www.businesswire.com/news/home/20260217981476/en/>

Media

Carolyn Hawley

Inizio Evoke Comms

Carolyn.Hawley@inizioevoke.com

media@sprucebio.com

Investors

Monique Kosse

Gilmartin Group

Monique@GilmartinIR.com

investors@sprucebio.com

Source: Spruce Biosciences, Inc.